Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of once-weekly GZR4 versus once-daily insulin glargine U100, both with insulin aspart, in adults with type 2 diabetes on basal-bolus insulin therapy
CTR20244856Phase 3Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of GZR4 in type 2 diabetes mellitus (T2DM), sponsored by Gannex Pharma Co., Ltd.. Started Feb 2025; status: completed.
02
Drugs
GZR4
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20244856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244856.